載入中
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
前收盤價
US$168.35
−US$1.73 · -1.02%
盤前
US$169.41
+US$1.06 · +0.63%
10月12日 上午8:35 ET
盤中時間採用ET。市場資料可能有所延遲。
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
日內區間
目前US$168.35
52週區間
目前US$168.35
盤中時間採用ET。市場資料可能有所延遲。
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
日內區間
目前US$168.35
52週區間
目前US$168.35
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 6.38億 USD | 3.86億 USD | 2.71億 USD | 5003.7萬 USD | — |
| 銷貨成本 | 4747.8萬 USD | 3330.3萬 USD | 2606.5萬 USD | 519.8萬 USD | — |
| 毛利 | 5.91億 USD | 3.52億 USD | 2.45億 USD | 4483.9萬 USD | — |
| 研究與開發 | 1.83億 USD | 1.87億 USD | 9794.4萬 USD | 5794.7萬 USD | 5806.1萬 USD |
| 銷售、一般及管理費用 | 5.71億 USD | 4.11億 USD | 3.23億 USD | 1.59億 USD | 6664.6萬 USD |
| 營業費用 | 7.6億 USD | 6.33億 USD | 4.76億 USD | 2.25億 USD | 1.25億 USD |
| 利息收入 | 937.1萬 USD | — | — | — | — |
| 利息支出 | 655.7萬 USD | 656.9萬 USD | 645.3萬 USD | 733.5萬 USD | 569.6萬 USD |
| 折舊和攤銷 | 906.4萬 USD | 795.8萬 USD | 683.4萬 USD | 440.2萬 USD | 7.6萬 USD |
| 營業利益 | −1.69億 USD | −2.81億 USD | −2.32億 USD | −1.8億 USD | −1.25億 USD |
| 淨利 | −1.83億 USD | −2.87億 USD | −2.39億 USD | −1.87億 USD | −1.3億 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$283
上漲空間 68.10%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2.76億0.01%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Morningstar Small-Cap ETFVB2億0.11%1853億 USD0.03%US$289.48+0.64%
Vanguard Morningstar Small-Cap Growth ETFVBK1.15億0.25%447億 USD0.05%US$344.74+1.22%
Vanguard Extended Market ETFVXF9971.92萬0.10%954億 USD0.05%US$235+0.80%
First Trust NYSE Arca Biotechnology Index FundFBT6519.2萬2.25%28.91億 USD0.55%US$265.4+2.00%
iShares Biotechnology ETFIBB5805.1萬0.55%108.2億 USD0.44%US$206.49+3.00%
iShares Russell Mid-Cap Growth ETFIWP4134.56萬0.21%200.95億 USD0.23%US$143.1+1.56%
Schwab U.S. Small-Cap ETFSCHA4017.26萬0.18%218.24億 USD0.03%US$32.79+0.40%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFFirst Trust NYSE Arca Biotechnology Index FundFBTiShares Biotechnology ETFIBBiShares Russell Mid-Cap Growth ETFIWPSchwab U.S. Small-Cap ETFSCHAAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
